Biocryst Pharmaceuticals (BCRX) Amortization of Deferred Charges (2011 - 2021)

Biocryst Pharmaceuticals has reported Amortization of Deferred Charges for 11 years, with the latest figure at $5.4 million in Q3 2021.

• For the quarter ending Q3 2021, Amortization of Deferred Charges rose 1320.47% year-over-year to $5.4 million; the trailing twelve-month figure through Sep 2021 stood at $15.3 million (up 2016.04% YoY), and the FY2023 full-year result was $8.5 million, changed N/A from the prior year.
• Amortization of Deferred Charges for Q3 2021 stood at $5.4 million, up from $3.9 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $5.4 million in Q3 2021, with the low at $209000.0 in Q4 2018.
• Historically, Amortization of Deferred Charges has averaged $1.1 million across 5 years, with a median of $255000.0 in 2019.
• Annual changes were most pronounced in 2018 — Amortization of Deferred Charges declined 4.13% — and 2021, when it soared 1320.47%.
• Biocryst Pharmaceuticals' Amortization of Deferred Charges stood at $218000.0 in 2017, then dropped by 4.13% to $209000.0 in 2018, then jumped by 63.64% to $342000.0 in 2019, then surged by 609.94% to $2.4 million in 2020, then jumped by 122.9% to $5.4 million in 2021.
• The last three Amortization of Deferred Charges figures came in at $5.4 million (Q3 2021), $3.9 million (Q2 2021), and $3.5 million (Q1 2021), per Business Quant data.